HIGHLIGHTS
- who: Christopher W. Schultz and Avinoam Nevler from the National Institutes of Health, Bethesda, MD, USA Jefferson Pancreas, Biliary, and Related Center, Department of Surgery, Thomas Jefferson University have published the paper: Pyrvinium Pamoate: Past, Present, and Future as an Anti-Cancer Drug, in the Journal: Biomedicines 2022, 3249 of /2022/
- what: In this review, the authors aim to explore both the history of pyrvinium and the data supporting pyrvinium as a clinically relevant cancer therapy. While ongoing, this trial PP as an anticancer agent, it was not until 2021 that the first clinical trial . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.